A Phase 1/2 trial of the TGFB2-specific antisense oligonucleotide trabedersen in patients with various solid tumors, including colorectal carcinoma, melanoma or pancreatic cancer, has reported that the treatment was safe and well tolerated, though further efficacy studies are pending. This evidence concerns the gene TGFB2 and colorectal carcinoma.